长期血液透析房颤患者口服抗凝治疗的系统评价与荟萃分析
该系统评价与荟萃分析纳入16项观察性研究(N=71,877),评估长期透析房颤患者口服抗凝药的疗效与安全性。与未抗凝相比,阿哌沙班与华法林未显著降低卒中/系统性血栓栓塞风险;华法林、达比加群和利伐沙班的大出血风险显著高于阿哌沙班和未抗凝。
要点
- 长期透析房颤患者中,阿哌沙班和华法林未显著降低卒中/系统性血栓栓塞风险。
- 华法林大出血风险显著高于阿哌沙班5mg、2.5mg及未抗凝。
- 达比加群和利伐沙班大出血风险也显著高于阿哌沙班和未抗凝。
核心结论
- 口服抗凝药未与长期透析房颤患者血栓栓塞风险降低相关。
- 华法林、达比加群和利伐沙班的大出血风险显著高于阿哌沙班和未抗凝。
- 口服抗凝药在该人群的获益-风险比需随机临床试验验证。
研究设计与样本
- 系统检索MEDLINE和EMBASE至2019年6月10日,纳入16项观察性研究,共71,877例长期透析合并房颤患者。
- 仅2项研究调查直接口服抗凝药,达比加群和利伐沙班结局仅限大出血事件。
主要发现
- 与未抗凝相比,阿哌沙班5mg(HR 0.59;95%CI 0.30-1.17)、阿哌沙班2.5mg(HR 1.00;95%CI 0.52-1.93)和华法林(HR 0.91;95%CI 0.72-1.16)未显著降低卒中/系统性血栓栓塞风险。
- 阿哌沙班5mg与较低死亡风险相关:对比华法林HR 0.65(95%CI 0.45-0.93),对比阿哌沙班2.5mg HR 0.62(95%CI 0.42-0.90),对比未抗凝HR 0.61(95%CI 0.41-0.90)。
- 华法林大出血风险显著高于阿哌沙班5mg(HR 1.41;95%CI 1.07-1.88)、阿哌沙班2.5mg(HR 1.40;95%CI 1.07-1.82)和未抗凝(HR 1.31;95%CI 1.15-1.50)。
- 达比加群和利伐沙班的大出血风险也显著高于阿哌沙班和未抗凝。
临床怎么用
- 长期透析房颤患者使用华法林、达比加群或利伐沙班时需警惕大出血风险。
- 阿哌沙班5mg可能与较低死亡风险相关,但需随机试验验证。
局限性
- 纳入研究均为观察性研究,仅2项调查直接口服抗凝药且结局限于大出血。
- 口服抗凝药在该人群的获益-风险比需随机临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients on long-term dialysis are at increased risk of bleeding. Although oral anticoagulants (OACs) are recommended for atrial fibrillation (AF) to reduce the risk of stroke, randomized trials have excluded these populations. As such, the net clinical benefit of OACs among patients on dialysis is unknown. OBJECTIVES: This study aimed to investigate the efficacy and safety of OACs in patients with AF on long-term dialysis. METHODS: MEDLINE and EMBASE were searched through June 10, 2019, for studies that investigated the efficacy and safety of different OAC strategies in patients with AF on long-term dialysis. The efficacy outcomes were ischemic stroke and/or systemic thromboembolism, all-cause mortality, and the safety outcome was major bleeding. RESULTS: This study identified 16 eligible observational studies (N = 71,877) regarding patients on long-term dialysis who had AF. Only 2 of 16 studies investigated direct OACs. Outcomes for dabigatran and rivaroxaban were limited to major bleeding events. Compared with no anticoagulants, apixaban and warfarin were not associated with a significant decrease in stroke and/or systemic thromboembolism (apixaban 5 mg, hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.30 to 1.17; apixaban 2.5 mg, HR: 1.00; 95% CI: 0.52 to 1.93; warfarin, HR: 0.91; 95% CI: 0.72 to 1.16). Apixaban 5 mg was associated with a significantly lower risk of mortality (vs. warfarin, HR: 0.65; 95% CI: 0.45 to 0.93; vs. apixaban 2.5 mg, HR: 0.62; 95% CI: 0.42 to 0.90; vs. no anticoagulant, HR: 0.61; 95% CI: 0.41 to 0.90). Warfarin was associated with a significantly higher risk of major bleeding than apixaban 5 min/2.5 mg and no anticoagulant (vs. apixaban 5 mg, HR: 1.41; 95% CI: 1.07 to 1.88; vs. apixaban 2.5 mg, HR: 1.40; 95% CI: 1.07 to 1.82; vs. no anticoagulant, HR: 1.31; 95% CI: 1.15 to 1.50). Dabigatran and rivaroxaban were also associated with significantly higher risk of major bleeding than apixaban and no anticoagulant. CONCLUSIONS: This meta-analysis showed that OACs were not associated with a reduced risk of thromboembolism in patients with AF on long-term dialysis. Warfarin, dabigatran, and rivaroxaban were associated with significantly higher bleeding risk compared with apixaban and no anticoagulant. The benefit-to-risk ratio of OACs in patients with AF on long-term dialysis warrants validation in randomized clinical trials.
引用
- Kuno T, Takagi H, Ando T, et al. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol. 2020. PMID: 31976865. doi:10.1016/j.jacc.2019.10.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。